-
公开(公告)号：US09283184B2
公开(公告)日：2016-03-15
申请号：US13130845
申请日：2009-11-24
IPC分类号： A61K35/17 , A61K38/19 , A61K9/127 , A61K9/51 , A61K31/7105 , A61K31/711 , A61K38/20 , A61K45/06 , A61K47/48 , B82Y5/00 , C12N5/00 , C12N5/0783 , C12N5/0789 , C12N15/87 , A61K39/00 , A61K39/395 , A61K47/46 , A61K35/12
CPC分类号： A61K9/127 , A61K9/146 , A61K9/19 , A61K9/5146 , A61K9/5153 , A61K31/7105 , A61K31/711 , A61K35/28 , A61K38/19 , A61K38/20 , A61K38/2086 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/06 , A61K47/46 , A61K47/6901 , A61K47/6911 , A61K47/6937 , A61K2035/124 , B82Y5/00 , C07K16/00 , C12N5/0006 , C12N5/0636 , C12N5/0647 , C12N15/113 , C12N15/87 , C12N2310/14 , A61K2300/00
摘要： The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.
摘要翻译： 本发明提供了通过将负载载体的纳米颗粒与具有归巢能力的细胞结合来将药剂递送到体内的局部区域，组织或器官的组合物和方法。 这些试剂可以分别是治疗剂或诊断剂，例如癌症化学治疗剂和成像剂。
-
公开(公告)号：US20110293705A1
公开(公告)日：2011-12-01
申请号：US13130845
申请日：2009-11-24
IPC分类号： A61K9/127 , A61K9/14 , A61P35/00 , A61P37/06 , A61P31/00 , A61K35/12 , C12N5/0783 , B82Y5/00
CPC分类号： A61K9/127 , A61K9/146 , A61K9/19 , A61K9/5146 , A61K9/5153 , A61K31/7105 , A61K31/711 , A61K35/28 , A61K38/19 , A61K38/20 , A61K38/2086 , A61K39/00 , A61K39/39 , A61K39/395 , A61K45/06 , A61K47/46 , A61K47/6901 , A61K47/6911 , A61K47/6937 , A61K2035/124 , B82Y5/00 , C07K16/00 , C12N5/0006 , C12N5/0636 , C12N5/0647 , C12N15/113 , C12N15/87 , C12N2310/14 , A61K2300/00
摘要： The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.
摘要翻译： 本发明提供了通过将负载载体的纳米颗粒与具有归巢能力的细胞结合来将药剂递送到体内的局部区域，组织或器官的组合物和方法。 这些试剂可以分别是治疗剂或诊断剂，例如癌症化学治疗剂和成像剂。
-
3.发明申请CONSTITUTIVE EXPRESSION OF COSTIMULATORY LIGANDS ON ADOPTIVELY TRANSFERRED T LYMPHOCYTES 有权化学成分在全身转移的淋巴细胞中的表达公开(公告)号：US20130121960A1
公开(公告)日：2013-05-16
申请号：US13595440
申请日：2012-08-27
申请人： Michel Sadelain , Matthias Stephan
发明人： Michel Sadelain , Matthias Stephan
CPC分类号： A61K35/17 , A61K38/2013 , A61K38/217 , A61K39/0011 , A61K45/06 , A61K2035/122 , A61K2035/124 , A61K2039/5156 , A61K2039/5158 , C12N5/0636 , C12N7/00 , C12N15/85 , C12N2501/25 , C12N2501/51 , C12N2501/599 , C12N2510/00 , C12N2799/04
摘要： The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
摘要翻译： 本发明提供免疫反应性细胞，包括表达至少一种抗原识别受体和共刺激配体的T细胞，细胞毒性T细胞，调节性T细胞和天然杀伤（NK）细胞，因此用于 治疗肿瘤和其他需要抗原特异性免疫应答增加的病理。
-
4.发明授权Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes 有权共培养配体对过继转移的T淋巴细胞的组成型表达公开(公告)号：US09220728B2
公开(公告)日：2015-12-29
申请号：US13595440
申请日：2012-08-27
申请人： Michel Sadelain , Matthias Stephan
发明人： Michel Sadelain , Matthias Stephan
CPC分类号： A61K35/17 , A61K38/2013 , A61K38/217 , A61K39/0011 , A61K45/06 , A61K2035/122 , A61K2035/124 , A61K2039/5156 , A61K2039/5158 , C12N5/0636 , C12N7/00 , C12N15/85 , C12N2501/25 , C12N2501/51 , C12N2501/599 , C12N2510/00 , C12N2799/04
摘要： The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
摘要翻译： 本发明提供免疫反应性细胞，包括表达至少一种抗原识别受体和共刺激配体的T细胞，细胞毒性T细胞，调节性T细胞和天然杀伤（NK）细胞，因此用于 治疗肿瘤和其他需要抗原特异性免疫应答增加的病理。
-
公开(公告)号：US08389282B2
公开(公告)日：2013-03-05
申请号：US12593751
申请日：2008-03-31
申请人： Michel Sadelain , Matthias Stephan
发明人： Michel Sadelain , Matthias Stephan
IPC分类号： C12N5/16
CPC分类号： A61K35/17 , A61K38/2013 , A61K38/217 , A61K39/0011 , A61K45/06 , A61K2035/122 , A61K2035/124 , A61K2039/5156 , A61K2039/5158 , C12N5/0636 , C12N7/00 , C12N15/85 , C12N2501/25 , C12N2501/51 , C12N2501/599 , C12N2510/00 , C12N2799/04
摘要： The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
-
公开(公告)号：US08252592B2
公开(公告)日：2012-08-28
申请号：US12593751
申请日：2008-03-31
申请人： Michel Sadelain , Matthias Stephan
发明人： Michel Sadelain , Matthias Stephan
IPC分类号： C12N5/16
摘要： The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
-
7.发明申请CONSTITUTIVE EXPRESSION OF COSTIMULATORY LIGANDS ON ADOPTIVELY TRANSFERRED T LYMPHOCYTES 有权化学成分在全身转移的淋巴细胞中的表达公开(公告)号：US20100178276A1
公开(公告)日：2010-07-15
申请号：US12593751
申请日：2008-03-31
申请人： Michel Sadelain , Matthias Stephan
发明人： Michel Sadelain , Matthias Stephan
CPC分类号： A61K35/17 , A61K38/2013 , A61K38/217 , A61K39/0011 , A61K45/06 , A61K2035/122 , A61K2035/124 , A61K2039/5156 , A61K2039/5158 , C12N5/0636 , C12N7/00 , C12N15/85 , C12N2501/25 , C12N2501/51 , C12N2501/599 , C12N2510/00 , C12N2799/04
摘要： The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing at least one of an antigen-recognizing receptor and a co-stimulatory ligand and methods of use therefore for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.
摘要翻译： 本发明提供免疫反应性细胞，包括表达至少一种抗原识别受体和共刺激配体的T细胞，细胞毒性T细胞，调节性T细胞和天然杀伤（NK）细胞，因此用于 治疗肿瘤和其他需要抗原特异性免疫应答增加的病理。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.024 秒)
